Proceedings of the Conference on Bioengineering for Global Health (SYMRESEARCH 2.0 2025)

Conference on Bioengineering for Global Health (SYMRESEARCH 2.0 2025)

📍Pune, India🗓️ 18-20 September 2025
<Previous Article In Volume
Next Article In Volume>

Leukemic Extracellular Vesicles as Drivers of a Pro-Inflammatory Niche

Authors
Vishakha Kasherwal1, Vaijayanti Kale2, Anuradha Vaidya1, 2, *
1Symbiosis School of Biological Sciences, Symbiosis International (Deemed University), Lavale, Pune, 412115, Maharashtra, India
2Symbiosis Centre for Stem Cell Research, Symbiosis International (Deemed University), Lavale, Pune, 412115, Maharashtra, India
*Corresponding author. Email: anuradha.vaidya@ssbs.edu.in
Corresponding Author
Anuradha Vaidya
Available Online 31 August 2026.
DOI
10.2991/978-94-6239-756-9_4How to use a DOI?
Keywords
Acute Myeloid Leukemia; Extracellular vesicles; Microvesicles; Exosomes; Mesenchymal stromal cells
Abstract

Acute myeloid leukemia (AML) cells often display resistance to conventional chemotherapy, partly due to the influence of AML-derived extracellular vesicles (AML-EVs). These vesicles, including microvesicles (MVs) and exosomes (Exos), play key roles in leukemic progression and bone marrow (BM) niche remodeling. This study investigates the effects of AML-EVs and their distinct subfractions on bone marrow–derived mesenchymal stromal cells (MSCs) and their associated functional properties. MSCs were primed with AML-EVs, AML-MVs, and AML-Exos isolated from the secretome of C1498 leukemic cells. Transcriptomic profiling revealed that AML-EVs, AML-MVs, and AML-Exos induced a pronounced pro-inflammatory transcriptional signature in MSCs. Furthermore, AML-EVs and their subfractions skewed MSCs differentiation toward the adipogenic lineage, suppressing osteogenic differentiation. Overall, this study identifies a previously unrecognized role of AML-EVs, including their fractions, viz. MVs and Exos, in reprogramming the BM niche which offer new insights into the mechanisms driving AML progression and chemoresistance. This would pave the way for developing novel niche-targeted therapies to combat AML.

Copyright
© 2026 The Author(s)
Open Access
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

<Previous Article In Volume
Next Article In Volume>
Volume Title
Proceedings of the Conference on Bioengineering for Global Health (SYMRESEARCH 2.0 2025)
Series
Advances in Biological Sciences Research
Publication Date
31 August 2026
ISBN
978-94-6239-756-9
ISSN
2468-5747
DOI
10.2991/978-94-6239-756-9_4How to use a DOI?
Copyright
© 2026 The Author(s)
Open Access
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Cite this article

risenwbib
TY  - CONF
AU  - Vishakha Kasherwal
AU  - Vaijayanti Kale
AU  - Anuradha Vaidya
PY  - 2026
DA  - 2026/08/31
TI  - Leukemic Extracellular Vesicles as Drivers of a Pro-Inflammatory Niche
BT  - Proceedings of the Conference on Bioengineering for Global Health (SYMRESEARCH 2.0 2025)
PB  - Atlantis Press
SP  - 33
EP  - 44
SN  - 2468-5747
UR  - https://doi.org/10.2991/978-94-6239-756-9_4
DO  - 10.2991/978-94-6239-756-9_4
ID  - Kasherwal2026
ER  -